Aurobindo Pharma achieves promising results for breast cancer biosimilar in Phase 3 trial

Aurobindo Pharma has announced positive results from a Phase 3 clinical trial of its breast cancer biosimilar product, BP02 (Trastuzumab or biosimilar to Herceptin), developed ... Read More